Figure 4.
The combination of therapeutic antibody and vaccine facilitate serum HBsAg clearance in AAV-HBV (A–D) Peripheral tolerance, AAV-HBV mice (n = 5/group; HBsAg: 1 × 103–2 × 104 IU/mL) were administrated with 400 μg 129G1 intravenously every 3 days as indicated by blue arrows, 12 μg CRT3-SEQ13 was administrated intramuscularly at day 30, day 44, day 51, day 58, day 65, and day 72 as indicated by red arrows. Start of vaccination was day 30. PBS was injected intravenously as control. (A) Schematic representation of the combination therapy procedure used for (B–D). (B-D) Time kinetic of virological indicators in AAV-HBV. Serum levels of (B) HBsAg, (C) anti-SEQ13 antibodies and (D) anti-CRT3-SEQ13 antibodies. Results were representative of three independent experiments. Statistical analyses were performed between red line and black line. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.